Senaste pressmeddelande
Finansiella rapporter
Aktieinformation
Handelsinformation
Glycorex-aktien är noterad och handlas på börsen Nordic Growth Market (NGM).
Glycorex Transplantation AB noterades på NGM Equity Stockholm 2001.
Symbol: GTAB B
ISIN-kod: SE0000524530
World-leader in
ABO-incompatible technologies
Glycosorb®-ABO enables blood group incompatible transplants. Glycosorb®-ABO reduce anti-A/B antibodies in human plasma through A/B antigen specific binding. Glycosorb®-ABO has been used clinically since 2001. It is used on four continents and has enabled more than 4,500 blood group incompatible organ transplants.
The company's product can help increase the availability of blood plasma, including convalescent plasma, by removing the blood group antibodies from blood group O-, A- and B- donor plasma. In this way, potential problems with immune-complex formation with, for example, the administration of AB plasma (containing soluble AB antigen) can be avoided. A number of units of our product has been delivered to a European hospital. Please contact us for further information.
The Glycorex Group possesses unique know-how and proficiency in the fields of biologically active carbohydrate substances and extracorporeal blood treatment. This provides the foundation for the development work that the subsidiaries Glycoprobe and Glycorex UBP are doing in the fields of autoimmune diseases and universal blood plasma respectively.